|
|
Home > Healthcare > Pharmaceutical > General Pharmaceutical
Primary Immune Deficiencies - An Overview
|
| Published Date:
October 2002
Published By:
Datamonitor
Page Count:
32
Order Code:
R313-4440
|
|
|
|
| Introduction: Primary immune deficiencies are inborn genetic defects in the immune system. It is estimated that at least half a million people worldwide suffer from at least one of these disorders. These patients suffer from recurrent and persistent infections. Gene therapy offers the promise of a potential cure, obliterating the need for antibiotic and immunoglobulin therapy and bone marrow transplants. Scope: * Examines disease etiology, symptoms and treatment options available to patients * Looks at the prevalence and diagnosis of some of the more common and defined conditions and discusses the prognosis for these individuals * Assesses unmet needs in the treatment of primary immune deficiencies and future opportunities, particularly in the area of gene therapy. Report Highlights: Prompt administration of antibiotics at the first signs of infection is vital and those with deficient antibody levels require monthly immunogobulin infusions. Bone marrow transplantation has provided complete remission to some suffering from very severe conditions, such as severe combined immunodeficiency disease (SCID), but global success rates over the past thirty years are only between 6070%. Gene therapy is beginning to show some promise as a viable treatment alternative. The obvious benefit in curing these debilitating illnesses will have to be balanced with the potential risks posed by this new form of treatment. Although entry into the commercial arena is not expected for another few years, the market and growth for gene therapy products will be unprecedented, since application of this technology will have far-reaching implications for a number of other clinical conditions. Reasons to Purchase: * Insightful overview of the key features of primary immune deficiencies, including prevalence, diagnosis and symptoms * Analyze current treatment options and prognosis for some of the more defined and common disorders * Identify unmet needs and learn about future opportunities, especially in gene therapy, which has enormous market potential
|
Similar Products
• United States Type 2 Diabetes Market
Published Nov 2009 by Intellent
• Company Financials: Bayer AG
Published Nov 2009 by Datamonitor
• Thailand Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Argentina Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Takeda Pipeline, Products, Performance, Potential
Published Nov 2009 by Espicom Healthcare Intelligence
• Poland Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Merck & Co. Performance, Products, Pipeline and Potential
Published Nov 2009 by Espicom Healthcare Intelligence
• Australia Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Nigeria Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Kenya Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
|
|
|
|
0 items
